South African universities have long been powerhouses in global health research, particularly in tackling HIV and tuberculosis challenges that resonate far beyond national borders. However, a sudden wave of funding cuts from the United States starting in early 2025 threatened to unravel decades of progress. The South African Medical Research Council (SAMRC), a statutory body dedicated to advancing health research, responded decisively with a comprehensive rescue grants program. This initiative has provided critical support to university-based research teams, helping to safeguard jobs, ongoing trials, and vital scientific infrastructure at institutions like the University of the Witwatersrand, University of Cape Town, and Stellenbosch University.

The cuts stemmed from policy shifts in the US, including a 90-day international aid pause and subsequent restrictions on sub-awards to foreign entities, especially those perceived as misaligned with certain US priorities. South Africa, the largest recipient of US National Institutes of Health (NIH) funding outside the US, saw direct grants plummet from around US$44 million across 102 awards in 2024 to US$34 million over 73 grants in 2025. Sub-award disruptions amplified the damage, with universities facing potential losses exceeding R200 million each in some cases. For higher education, this meant not just halted projects but risks to postgraduate training, staff retention, and institutional research capacity.

Understanding the Scale of Disruption at South African Universities

The impact on higher education was profound. At the University of Cape Town (UCT), for instance, 22 active projects valued at R172 million received stop-work orders by mid-2025, affecting clinical trials and epidemiological studies. The University of the Witwatersrand (Wits) and Stellenbosch University reported similar shocks, with research units like the Desmond Tutu Health Foundation and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) facing tens of millions in shortfalls. These cuts jeopardized 39 TB and HIV clinical sites nationwide, putting 27 HIV trials and 20 TB trials at risk, many hosted at university-affiliated labs.

Early-career researchers, including PhD students and postdocs funded through these grants, were particularly vulnerable. Many first-time NIH awardees saw their careers stall, with job losses projected for over 110 staff at SAMRC-supported sites alone. Universities scrambled to reallocate internal funds, but the scale overwhelmed budgets already strained by post-pandemic recoveries and domestic enrollment pressures. The ripple effects extended to teaching, as research-active faculty balanced lab shutdowns with lecture halls, potentially eroding South Africa's competitive edge in global health rankings.

Beyond immediate halts, the cuts disrupted long-term platforms like biobanks and cohort studies built over years. For example, newborn and child health initiatives at universities risked losing momentum just as they neared breakthroughs in maternal interventions. Non-communicable disease research, though less dominant, also suffered, highlighting the broad vulnerability of university research portfolios heavily reliant on foreign donors.

SAMRC's Swift Response: Securing R600 Million in Rescue Funds

In a coordinated effort, the SAMRC rallied R600 million by August 2025, blending government commitment with international philanthropy. National Treasury contributed R400 million, matched by R100 million each from the Bill & Melinda Gates Foundation and Wellcome Trust, plus R14.4 million from the ELMA Foundation. This 'Support for the South African National Health Research Enterprise in Response to USA Funding Withdrawals' package marked a historic public-private pivot, prioritizing ecosystem preservation over siloed project funding.

Funds were earmarked for three years, with R115 million disbursed in the 2025/2026 financial year alone. Unlike traditional competitive grants, these targeted groups with active or recently terminated US-funded projects at public universities and research entities. Institutions committed matching funds for staff salaries, allowing SAMRC allocations to cover direct project costs like participant care, lab supplies, and ethical wind-downs. This hybrid model ensured sustainability, preventing a total collapse while buying time for diversification. Spotlight's detailed coverage underscores how this approach addressed the chaotic rollout of US cuts.

The Application Process and Award Outcomes

Two requests for applications (RFAs) were issued—in July and December 2025—to navigate evolving US decisions, where some grants were reinstated mid-process. Of 102 submissions, 28 were withdrawn after funding restorations, leaving 74 for review. Ultimately, 59 projects secured approval, spanning HIV (29%), tuberculosis (40%), newborn/child health (12%), non-communicable diseases (9%), and other infectious diseases (10%).

• HIV-focused efforts maintained prevention trials and vaccine studies at university sites.
• TB research preserved drug resistance surveillance and novel therapy platforms.
• Child health initiatives protected longitudinal cohorts tracking developmental outcomes.

University research offices played key roles, submitting on behalf of principal investigators. The process emphasized ethical continuity, ensuring trials could conclude responsibly or transition to care. By April 2026, funds were rolling out, stabilizing teams and averting mass layoffs.

Spotlight on University Case Studies

While specific recipients remain aggregated for privacy, patterns emerge from institutional reports. At Wits, SAMRC support bridged gaps in its Perinatal HIV Research Unit, sustaining mother-infant transmission studies critical for global guidelines. UCT's Desmond Tutu HIV Centre used grants to retain bioinformaticians analyzing genomic data from PEPFAR cohorts, preventing data silos.

Stellenbosch University's Centre for Tuberculosis Research Innovation accessed funds for aerosol transmission modeling, vital amid rising drug-resistant strains. The University of KwaZulu-Natal (UKZN), home to CAPRISA, preserved Phase III trial follow-ups, ensuring participant safety and data integrity. These examples illustrate how rescue grants not only saved projects but fortified university research cores against future shocks. For deeper insights into Wits' challenges, their official update details the R1.85 billion national loss.

Stakeholder Perspectives: Voices from Academia

Professor Ntobeko Ntusi, SAMRC President, warned of 'catastrophic' risks, noting US sources comprised 28% of SAMRC's budget. Dr. Michelle Mulder, SAMRC's executive director for grants, stressed preserving 'infrastructure, people, projects, and platforms' built over generations. University leaders echoed this: UCT's Deputy Vice-Chancellor for Research highlighted long-term capacity erosion, while Wits advocated for diversified portfolios.

Early-career academics praised the grants for protecting traineeships, with postdocs at Stellenbosch crediting SAMRC for PhD completions. Student bodies at UKZN urged permanent local funding mechanisms, viewing the crisis as a wake-up for self-reliance.

Challenges Overcome and Lessons for Higher Education

Implementation wasn't seamless. Shifting US policies forced dual RFAs, and quantifying sub-award losses proved tricky due to opaque NIH tracking. Universities bridged staff costs, but administrative burdens mounted. Yet, successes abound: No major trial abandonments, minimal job losses, and retained expertise.

Lessons include funding diversification—courting EU, UK, and African Union sources—and bolstering internal grants. SAMRC's model of institutional matching fostered partnerships, modeling collaborative resilience for higher ed.

Future Outlook: Flagship Programs and Sustainable Research

With first-year disbursements complete, SAMRC eyes a legacy flagship grant scheme, channeling remaining funds strategically. Universities are pivoting: Wits launched Africa-focused consortia, UCT eyes Wellcome extensions. This crisis accelerates National Research Foundation reforms, promising R1 billion+ annual boosts.

For students and faculty, opportunities emerge in clinician-scientist tracks and entrepreneurship, positioning SA universities as innovation hubs. SAMRC's race to rescue narrative inspires a bolder, homegrown research era.

Photo by Mathurin NAPOLY / matnapo on Unsplash

Actionable Insights for Researchers and Institutions

Aspiring academics should target SAMRC's clinician-researcher programs, while universities invest in grant-writing hubs. Diversify via Horizon Europe or African Centres of Excellence. Track RFAs diligently, as future calls prioritize sustainability.

• Build multi-funder portfolios early.
• Leverage university matching commitments.
• Prioritize ethical trial transitions.
• Engage alumni for philanthropy.

This episode underscores higher education's pivot from dependency to agency, ensuring South Africa's research legacy endures.